ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide.
Antonio Carlo BossiValentina De MoriCristiana ScarannaGiovanni VeronesiGiuseppe Leporenull nullPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2020)
Dulaglutide is an effective drug for the treatment of T2D that is administered once weekly using a simple auto-injector device. Real-life data confirm the observations in randomized controlled trials that persistent treatment with dulaglutide may help patients with T2D achieve an improvement in some metabolic features and in body weight. It is important that the benefits of therapy with dulaglutide, i.e., the effects of the "glycemic" and the so-called "extra-glycemic" actions of GLP-1RAs, are supported by diabetes care teams emphasizing the need for patients to maintain a healthy lifestyle.
Keyphrases
- body weight
- type diabetes
- end stage renal disease
- cardiovascular disease
- metabolic syndrome
- emergency department
- chronic kidney disease
- stem cells
- systematic review
- combination therapy
- cross sectional
- prognostic factors
- physical activity
- mesenchymal stem cells
- peritoneal dialysis
- adipose tissue
- bone marrow
- replacement therapy
- electronic health record
- smoking cessation
- glycemic control
- drug induced